| Daclizumab (USAN/INN) |
| Basiliximab (USAN/INN); Basiliximab (genetical recombination) (JAN) <JP/US> |
| Anakinra (USAN/INN) <US> |
| Rilonacept (USAN/INN) <US> |
| Ustekinumab (USAN/INN); Ustekinumab (genetical recombination) (JAN); Ustekinumab (genetical recombination) [Ustekinumab biosimilar 1] (JAN); Ustekinumab (genetical recombination) [Ustekinumab biosimilar 2] (JAN) <JP/US> |
| Tocilizumab (USAN/INN); Tocilizumab (genetical recombination) (JAN) <JP/US> |
| Canakinumab (USAN/INN); Canakinumab (genetical recombination) (JAN) <JP/US> |
| Briakinumab (USAN/INN) |
| Secukinumab (USAN/INN); Secukinumab (genetical recombination) (JAN) <JP/US> |
| Siltuximab (USAN/INN) <US> |
| Brodalumab (USAN); Brodalumab (genetical recombination) (JAN) <JP/US> |
| Ixekizumab (USAN); Ixekizumab (genetical recombination) (JAN) <JP/US> |
| Sarilumab (USAN); Sarilumab (genetical receombination) (JAN) <JP/US> |
| Sirukumab (USAN); Sirukumab (genetical recombination) (JAN) |
| Guselkumab (USAN/INN); Guselkumab (genetical recombination) (JAN) <JP/US> |
| Tildrakizumab (USAN); Tildrakizumab (genetical recombination) (JAN) <JP/US> |
| Risankizumab (USAN/INN); Risankizumab (genetical recombination) (JAN) <JP/US> |
| Satralizumab (USAN/INN); Satralizumab (genetical recombination) (JAN) <JP/US> |
| Bimekizumab (USAN/INN); Bimekizumab (genetical recombination) (JAN) <JP/US> |
| Spesolimab (USAN/INN); Spesolimab (genetical recombination) (JAN) <JP/US> |
| Olokizumab (INN) |
| Mirikizumab (USAN/INN); Mirikizumab (genetical recombination) (JAN) <JP/US> |
| Levilimab (INN) |
| Anti-human thymocyte immunoglobulin, rabbit (JAN) <JP/US> |
| Pirfenidone (JAN/USAN/INN) <JP/US> |
| Reslizumab (USAN) <US> |
| Mepolizumab (USAN/INN); Mepolizumab (genetical recombination) (JAN) <JP/US> |
| Benralizumab (USAN/INN); Benralizumab (genetical recombination) (JAN) <JP/US> |
| Dupilumab (USAN/INN); Dupilumab (genetical recombination) (JAN) <JP/US> |
| Tralokinumab (USAN/INN); Tralokinumab (genetical recombination) (JAN) <JP/US> |
| Lebrikizumab (USAN/INN); Lebrikizumab (genetical recombination) (JAN) <JP/US> |
| Nemolizumab (USAN/INN); Nemolizumab (genetical recombination) (JAN) <JP/US> |
| Lisofylline (USAN/INN) |
| Apilimod mesylate (USAN) |
| Anrukinzumab (USAN) |
| Fezakinumab (USAN/INN) |
| Enokizumab (USAN/INN) |
| Gevokizumab (USAN/INN) |
| Afasevikumab (USAN/INN) |
| Brazikumab (USAN/INN) |
| Tibulizumab (USAN/INN) |
| Etokimab (USAN) |
| Isunakinra (USAN/INN) |
| Itepekimab (USAN/INN) |
| Depemokimab (USAN); Depemokimab (genetical recombination) (JAN) |
| Izokibep (USAN/INN) |
| Ordesekimab (USAN) |
| Lutikizumab (INN) |
| Tozorakimab (USAN/INN); Tozorakimab (genetical recombination) (JAN) |
| Lusvertikimab (USAN/INN) |
| Ziltivekimab (USAN/INN) |
| Vamikibart (USAN/INN) |
| Tilrekimig (USAN) |
| Ompekimig (USAN) |